About

The Accelerating Medicines Partnership (AMP®) Schizophrenia (SCZ) program aims to clarify the disease pathways and long-term outcomes of people who are at risk for schizophrenia and to identify new and better targets for early treatment.

Data Processing, Analysis, and Coordination Center

The National Institute of Mental Health (NIMH) is supporting the Psychosis Risk Evaluation, Data Integration, and Computational Technologies (PREDICT): Data Processing, Analysis, and Coordination Center as part of the Accelerating Medicines Partnership (AMP®) SCZ program.

Martha E. Shenton, Ph.D., Professor of Psychiatry and Radiology at Harvard Medical School and Founding Director of the Psychiatry Neuroimaging Laboratory at Brigham and Women’s Hospital, and Rene Kahn, M.D., Ph.D, Chair of the Department of Psychiatry and Behavioral Health at Icahn School of Medicine at Mount Sinai, are leading a project creating a data processing, analysis, and coordination center that will integrate and analyze CHR biomarker and clinical data generated by the two multisite research networks as well as key existing CHR-related datasets. Using these data, the researchers plan to develop algorithms that can identify biomarkers that predict CHR outcomes — biomarkers that can then be used to identify clinically useful subtypes of CHR.

Co-Directors